Initial jobless claims fell by 16,000 to 199,000 in the week ended Dec. 27, the Labor Department said Wednesday.  It is the third straight weekly decline. ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key Takeaways QS is advancing solid-state batteries, delivering B1 samples and reporting first customer billings.Toyota has begun production at its North Carolina battery plant, targeting 30 GWh annually at full capacity.Tesla says its 4680 cells are now cheaper in-house, while balancing supply from partners as it scales.Electric vehicles (EVs) are becoming a core part of global transportation. Improvements in battery technology are a major reason for that. Today’s EV batteries last longer, charge faster an ...

核心财务表现 - 公司第二季度销售额为11,603,472美元，较去年同期的8,548,881美元大幅增长[1] - 公司第二季度净利润为2,008,624美元，较去年同期的1,056,160美元大幅增长[2] - 公司上半财年销售额为21,521,822美元，高于去年同期的20,166,737美元[1] - 公司上半财年净利润为4,198,708美元，高于去年同期的3,722,815美元[2] - 第二季度每股收益为0.64美元，去年同期为0.34美元[4] - 上半财年每股收益为1.33美元，去年同期为1.19美元[4] 管理层评论与业绩驱动因素 - 公司第二季度销售额创下1,160万美元的新纪录，超越了2023财年创下的1,050万美元的旧纪录[3] - 公司上半财年销售额创下2,150万美元的新纪录，超越了2024财年创下的2,030万美元的旧纪录[3] - 第二季度和上半财年盈利同比增长分别为90%和13%，主要得益于销量增长和高效执行[3] - 公司积压订单为2,510万美元，较本财年初的2,710万美元略有下降，主要原因是订单接收时间与交付时间的差异[3] 市场与业务展望 - 航空航天/国防市场客户活动的增加，持续抵消了结构工程和工业市场客户所面临的阻力[3] - 公司凭借新近建成的开发实验室，将在下半财年继续积极瞄准其三大目标市场（航空航天/国防、结构工程、工业）中客户急需并重视其定制工程产品的机会[3] - 公司将继续致力于在国内航空航天和国防市场以及全球结构建筑和工业市场实现增长[3] 公司背景 - Taylor Devices Inc 是一家拥有70年历史的公司，从事用于各类车辆、机械、设备和结构的减震、速率控制和能量存储装置的设计、开发、制造和销售[3]

If you want full access to all our reports, data, and investing ideas, join The Aerospace Forum , the #1 aerospace, defense, and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.FTAI Aviation ( FTAI ) suffered a significant shock at the start of 2025. However, in my view, that offered a strong buy opportunity, and looking at the stock price performance of the aero engine leasingDhierin-Perkash Bechai is an aerospace, def ...

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux.Dear BioMark Shareholders and Team,As we reflect on 2025, we celebrate a transformative year that positions BioMark as the leader in early cancer detectio ...

thBEAVERTON, Ore.--(BUSINESS WIRE)--Digimarc Corporation (Nasdaq: DMRC), a pioneer and global leader in digital identity and authentication solutions, will attend the 28 Annual Needham Growth Conference in New York on Tuesday, January 13, 2026. Digimarc President and CEO Riley McCormack and CFO Charles Beck will host meetings at the event, which is being held at the Lotte New York Palace Hotel. The Needham research team has individually selected the attending companies. If you want additional information o ...

New orders strengthen Ondas' record 2025 trajectory across counter-UAS, UAS, UGVs, and other mission-critical security capabilities Momentum builds on Ondas' expanding multi-domain autonomy portfolio and growing international program activity BOSTON, MA / ACCESS Newswire / December 31, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence through its Ondas Autonomous Systems ( OAS ) business unit and private wireless soluti ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CY ...

DALLAS, TX / ACCESS Newswire / December 31, 2025 / Auri Inc. (OTCID:AURI), a cutting-edge driven incubating holding company, releases end of year report with excitement for the Productive New Year 2026. The company wished to thank all its loyal shareholders, investors and stakeholders for their steadfast support and great vote of confidence. ...